<DOC>
	<DOC>NCT02448797</DOC>
	<brief_summary>Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small cell lung cancer patients with EGFR mutation. The primary endpoint is disease-free survival.</brief_summary>
	<brief_title>Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Pathologically confirmed lung adenocarcinoma after surgical resection Stage IIIIIA disease according to 7th edition of TNM staging Positive EGFR gene mutation (19/21) ECOG 01 At least 1year life expectancy Adequate organ function Previous systemic antitumor therapy, including chemotherapy or targeted therapy(Including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ Pneumonectomy of right lung Any unresolved chronic toxicity from previous anticancer therapy Allergic to study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>